EX-99.7 7 d112314dex997.htm EX-99.7

EX-99.7

Exhibit 99.7

Joint Filing Agreement

In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them of a statement on Schedule 13D (including amendments thereto) with respect to the common stock, par value $0.001 per share, of Pandion Therapeutics, Inc., a Delaware corporation, and further agree that this Joint Filing Agreement be included as an Exhibit to such joint filings. In evidence thereof, the undersigned, being duly authorized, have executed this Joint Filing Agreement as of the date set forth below.

Date: March 4, 2021				MERCK & CO. INC.
				/s/ Robert M. Davis
				Name:		Robert M. Davis
				Title:		Executive Vice President, Global Services and Chief Financial Officer
				MERCK SHARP & DOHME CORP.
				/s/ Sunil A. Patel
				Name:		Sunil A. Patel
				Title:		Senior Vice President, Corporate Development
				PANAMA MERGER SUB, INC.
				/s/ Rita Karachun
				Name:		Rita Karachun
				Title:		President